\u3010\u6587\u732e\u540d\u3011
\n\u8457\u8005\u540d\uff1aDean A. Seehusen et al.\u00a0
\n\u6587\u732e\u30bf\u30a4\u30c8\u30eb\uff1aStatins for Primary Cardiovascular Prevention: Cochrane for Clinicians Putting Evidence to Practice.
\n\u96d1\u8a8c\u540d\u30fb\u66f8\u7c4d\u540d\uff1aAmerican Family Physician.
\n\u767a\u884c\u5e74\uff1a\u00a02011; 84(7): 767-769.<\/p>\n
\u3010\u8981\u7d04\u3011
\n\uff1c\u30b1\u30fc\u30b9\uff1e
\n54\u6b73\u306e\u7537\u6027\u304c\u5065\u8a3a\u306e\u76ee\u7684\u3067\u53d7\u8a3a\u3057\u305f\u3002\u7279\u8a18\u3059\u3079\u304d\u65e2\u5f80\u6b74\u306f\u306a\u304f\u3001\u55ab\u7159\u306a\u3057\u3001\u5fc3\u8840\u7ba1\u75be\u60a3\u306e\u52a0\u5897\u6b74\u306a\u3057\u3002\u6295\u85ac\u306a\u3057\u3002BMI\u304c26\u3067\u3042\u308b\u3053\u3068\u3092\u9664\u3051\u3070\u8eab\u4f53\u8a3a\u5bdf\u306b\u7570\u5e38\u306f\u8a8d\u3081\u3089\u308c\u306a\u3044\u3002Tcho 256mg\/dl\u3000HDL 51mg\/dl\u3000LDL 162mg\/dl\u3002\u3042\u306a\u305f\u306f\u5f7c\u306e\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u30ec\u30d9\u30eb\u3092\u4e0b\u3052\u308b\u305f\u3081\u306b\u30b9\u30bf\u30c1\u30f3\u3092\u6295\u4e0e\u3059\u308b\u3053\u3068\u3092\u8003\u616e\u3057\u305f\u304c\u5f7c\u306e\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306e\u30ea\u30b9\u30af\u304c\u4e0b\u3052\u3089\u308c\u308b\u304b\u3069\u3046\u304b\u7591\u554f\u306b\u601d\u3063\u305f\u3002<\/p>\n
\uff1c\u81e8\u5e8a\u4e0a\u306e\u7591\u554f\uff1e
\n\u30b9\u30bf\u30c1\u30f3\u306f\u51a0\u8840\u7ba1\u75be\u60a3\u306e\u65e2\u5f80\u306e\u306a\u3044\u4eba\u306e\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u30a4\u30d9\u30f3\u30c8\u3092\u6e1b\u3089\u3059\u304b\uff1f
\n\uff1c\u30a8\u30d3\u30c7\u30f3\u30b9\u306b\u57fa\u3065\u3044\u305f\u89e3\u7b54\uff1e
\n\u3053\u308c\u307e\u3067\u306e\u81e8\u5e8a\u7814\u7a76\u3067\u306f\u30b9\u30bf\u30c1\u30f3\u306f\u7dcf\u6b7b\u4ea1\u3001\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u8907\u5408\u30a2\u30a6\u30c8\u30ab\u30e0\u3001\u8840\u884c\u518d\u5efa\u8853\u3092\u6e1b\u5c11\u3055\u305b\u308b\u3053\u3068\u3092\u793a\u3057\u3066\u304d\u305f\u3002\u3057\u304b\u3057\u306a\u304c\u3089\u3001\u591a\u304f\u306e\u81e8\u5e8a\u7814\u7a76\u306f\u591a\u6570\u306e\u5fc3\u8840\u7ba1\u75be\u60a3\u306e\u65e2\u5f80\u3092\u6301\u3064\u60a3\u8005\u304c\u542b\u307e\u308c\u3066\u3044\u308b\u3002\u521d\u56de\u306e\u5fc3\u8840\u7ba1\u7cfb\u30a4\u30d9\u30f3\u30c8\u306e\u4e88\u9632\u306b\u5bfe\u3059\u308b\u30b9\u30bf\u30c1\u30f3\u306e\u52b9\u679c\u3092\u793a\u3059\u6b63\u78ba\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\u4e0d\u8db3\u3057\u3066\u3044\u308b\u3002<\/p>\n
\u2015Cochrane systematic review\u306e\u8981\u7d04\u2015
\n\uff1c\u76ee\u7684\uff1e
\n\u5fc3\u8840\u7ba1\u75be\u60a3\u306e\u65e2\u5f80\u306e\u306a\u3044\u4eba\u306b\u304a\u3051\u308b\u30b9\u30bf\u30c1\u30f3\u306e\u52b9\u679c\uff08benefit\u3068harm\u53cc\u65b9\uff09\u3092\u8a55\u4fa1\u3059\u308b\u3002
\n\uff08\u6587\u732e\u691c\u7d22\u306e\u65b9\u6cd5\uff09
\n\u691c\u7d22\u306e\u52b4\u529b\u304c\u91cd\u8907\u3059\u308b\u3053\u3068\u3092\u3055\u3051\u308b\u305f\u3081\u3001\u904e\u53bb\u306e\u30b7\u30b9\u30c6\u30de\u30c6\u30a3\u30c3\u30af\u30ec\u30d3\u30e5\u30fc\u306e\u4e00\u89a7\u3092\u30c1\u30a7\u30c3\u30af\u3057\u305f\u3002\u305d\u306e\u5f8c\u3001Cochrane Central Register of Controlled Trials (Issue1, 2007)\u3001Medline\uff082001-2007\u5e743\u6708\uff09\u3001EMBASE\uff082003-2007\u5e743\u6708\uff09\u3092\u691c\u7d22\u3057\u305f\u3002\u8a00\u8a9e\u306b\u3088\u308b\u5236\u9650\u306f\u3057\u306a\u304b\u3063\u305f\u3002
\n\uff08\u6587\u732e\u9078\u629e\u306e\u57fa\u6e96\uff09
\n1\u5e74\u4ee5\u4e0a\u30b9\u30bf\u30c1\u30f3\u3092\u6295\u4e0e\u30576\u304b\u6708\u4ee5\u4e0a\u306e\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u3092\u884c\u3063\u305f\u6210\u4eba\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u3002LDL\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u3001HDL\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u3069\u3061\u3089\u3092\u6e2c\u5b9a\u3057\u3066\u3044\u3066\u3082\u826f\u3044\u3053\u3068\u3068\u3057\u305f\u3002\u5fc3\u8840\u7ba1\u75be\u60a3\u306e\u65e2\u5f80\u306e\u3042\u308b\u60a3\u8005\u304c10\uff05\u4ee5\u4e0b\u306e\u8a66\u9a13\u3092\u9078\u629e\u3057\u305f\u3002
\n\uff08\u30c7\u30fc\u30bf\u53ce\u96c6\u3068\u5206\u6790\uff09
\n2\u540d\u306e\u8457\u8005\u304c\u72ec\u7acb\u3057\u3066\u4f5c\u696d\u3092\u884c\u3063\u305f\u3002\u30a2\u30a6\u30c8\u30ab\u30e0\u306b\u306f\u7dcf\u6b7b\u4ea1\u3001\u81f4\u6b7b\u7684\u30fb\u975e\u81f4\u6b7b\u7684\u51a0\u8840\u7ba1\u75be\u60a3\u3001\u5fc3\u8840\u7ba1\u75be\u60a3\u3001\u8133\u5352\u4e2d\u3001\u8907\u5408\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3001\u7dcf\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u5024\u306e\u5909\u52d5\u3001\u8840\u884c\u518d\u5efa\u8853\u3001\u526f\u4f5c\u7528\u3001QOL\u3001\u30b3\u30b9\u30c8\u304c\u542b\u307e\u308c\u305f\u3002
\n\u975e\u9023\u7d9a\u30c7\u30fc\u30bf\u3068\u3057\u3066Relative risk (RR) \u3001\u9023\u7d9a\u30c7\u30fc\u30bf\u3068\u3057\u3066pooled weighted \u5e73\u5747\u5024\u306e\u5dee\uff0895%CI\u3082\uff09\u3092\u8a08\u7b97\u3057\u305f\u3002
\n\uff08\u7d50\u679c\uff09
\n14\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\uff0834,272\u4eba\uff09\u304c\u9078\u629e\u3055\u308c\u305f\u300211\u306e\u8a66\u9a13\u304c\u7279\u5b9a\u306e\u6761\u4ef6\u4e0b\u306b\u3042\u308b\u60a3\u8005\uff08\u8102\u8cea\u306e\u4e0a\u6607\u3001\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u5727\u3001\u5fae\u91cf\u30a2\u30eb\u30d6\u30df\u30f3\u5c3f\uff09\u3092\u5bfe\u8c61\u3068\u3057\u3066\u3044\u305f\u3002\u30b9\u30bf\u30c1\u30f3\u306e\u6295\u4e0e\u306b\u3088\u308a\u7dcf\u6b7b\u4ea1\u306f\u6e1b\u5c11\uff08RR\uff1d0.83; 95%CI\u30000.73-0.95\uff09\u3001\u81f4\u6b7b\u7684\u30fb\u975e\u81f4\u6b7b\u7684\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u8907\u5408\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3082\u540c\u69d8\u306b\u6e1b\u5c11\uff08RR\uff1d0.70; 95%CI\u30000.61-0.79\uff09\u3057\u305f\u3002\u8840\u884c\u518d\u5efa\u8853\u306b\u3064\u3044\u3066\u3082\u540c\u69d8\u306e\u7d50\u679c\uff08RR\uff1d0.66; 95%CI\u30000.53-0.83\uff09\u3067\u3042\u3063\u305f\u3002\u7dcf\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u5024\u3001LDL\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u5024\u306f\u3059\u3079\u3066\u306e\u8a66\u9a13\u306b\u304a\u3044\u3066\u6e1b\u5c11\u3057\u3066\u3044\u305f\u304c\u3001\u305d\u306e\u7a0b\u5ea6\u306f\u4e0d\u5747\u4e00\u3067\u3042\u3063\u305f\u3002\u30b9\u30bf\u30c1\u30f3\u306e\u6295\u4e0e\u306b\u3088\u308b\u91cd\u5927\u306a\u526f\u4f5c\u7528\u3084QOL\u306b\u5bfe\u3059\u308b\u78ba\u5b9f\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\u3002
\n\uff08\u7d50\u8ad6\uff09
\n\u30b9\u30bf\u30c1\u30f3\u306f\u91cd\u5927\u306a\u6709\u5bb3\u4e8b\u8c61\u3092\u5897\u3084\u3059\u3053\u3068\u306a\u304f\u7dcf\u6b7b\u4ea1\u3001\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u8907\u5408\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3001\u8840\u884c\u518d\u5efa\u8853\u3092\u6e1b\u5c11\u3055\u305b\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\u304c\u3001\u6709\u5bb3\u4e8b\u8c61\u3092\u5831\u544a\u3057\u3066\u3044\u306a\u3044\u8a66\u9a13\u3084\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u3092\u65e2\u5f80\u306b\u6301\u3064\u60a3\u8005\u3092\u542b\u3093\u3067\u3044\u305f\u308a\u3001\u9078\u629e\u7684\u306b\u30a2\u30a6\u30c8\u30ab\u30e0\u3092\u5831\u544a\u3057\u3066\u3044\u308b\u3082\u306e\u3082\u8a8d\u3081\u3089\u308c\u305f\u3002\u30b9\u30bf\u30c1\u30f3\u306b\u3088\u308bPrimary prevention\u304c\u8cbb\u7528\u5bfe\u52b9\u679c\u306b\u512a\u308c\u3066\u3044\u308b\u304b\u3001\u60a3\u8005\u306eQOL\u3092\u6539\u5584\u3059\u308b\u304b\u3068\u8a00\u3046\u70b9\u306b\u95a2\u3057\u3066\u306f\u9650\u3089\u308c\u305f\u30a8\u30d3\u30c7\u30f3\u30b9\u3057\u304b\u306a\u3044\u3002\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u30ea\u30b9\u30af\u306e\u4f4e\u3044\u60a3\u8005\u306b\u5bfe\u3057\u3066\u30b9\u30bf\u30c1\u30f3\u3092\u6295\u4e0e\u3059\u308b\u3053\u3068\u306b\u3064\u3044\u3066\u306f\u614e\u91cd\u3067\u3042\u308b\u3079\u304d\u3067\u3042\u308b\u3002<\/p>\n
\uff1c\u30b3\u30e1\u30f3\u30c8\uff1e
\n\u3000\u3053\u306e\u30ec\u30d3\u30e5\u30fc\u306f\u5fc3\u8840\u7ba1\u7cfb\u30a4\u30d9\u30f3\u30c8\u306ePrimary prevention\u306b\u30b9\u30bf\u30c1\u30f3\u306f\u6709\u52b9\u3067\u306f\u306a\u3044\u3053\u3068\u3092\u793a\u3057\u3066\u3044\u308b\u308f\u3051\u3067\u306f\u306a\u3044\u304c\u3001\u5fc3\u8840\u7ba1\u75be\u60a3\u3092\u6709\u3055\u306a\u3044\u60a3\u8005\u306b\u304a\u3051\u308b\u30b9\u30bf\u30c1\u30f3\u4f7f\u7528\u3092\u61f8\u5ff5\u3059\u308b\u6587\u732e\u306e\u6ce8\u76ee\u3059\u3079\u304d\u30ae\u30e3\u30c3\u30d7\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u308b\u3002\u521d\u56de\u306e\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u3092\u4e88\u9632\u3059\u308b\u305f\u3081\u306b\u30b9\u30bf\u30c1\u30f3\u3092\u6295\u4e0e\u3059\u308b\u304b\u3069\u3046\u304b\u3092\u6c7a\u5b9a\u3059\u308b\u969b\u306b\u306f\u3059\u3067\u306b\u59a5\u5f53\u6027\u304c\u8a55\u4fa1\u3055\u308c\u3066\u3044\u308bFramingham risk score\u306b\u3088\u308b\u60a3\u8005\u306e\u30ea\u30b9\u30af\u8a55\u4fa1\u304c\u3057\u3063\u304b\u308a\u884c\u308f\u308c\u308b\u3079\u304d\u3067\u3042\u308d\u3046\u3002\u30ea\u30b9\u30af\u304c\u975e\u5e38\u306b\u9ad8\u3044\u60a3\u8005\u3067\u306f\u30b9\u30bf\u30c1\u30f3\u306e\u6295\u4e0e\u306f\u6709\u52b9\u3067\u3042\u308d\u3046\u3002\u4e2d\u7b49\u5ea6\u3001\u8efd\u5ea6\u30ea\u30b9\u30af\u306e\u60a3\u8005\u3067\u306f\u30b9\u30bf\u30c1\u30f3\u4f7f\u7528\u306e\u6709\u52b9\u6027\u304c\u660e\u3089\u304b\u3067\u306f\u306a\u3044\u305f\u3081\u3001\u60a3\u8005\u306b\u306f\u3053\u306e\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u30ae\u30e3\u30c3\u30d7\u3092\u4f1d\u3048\u3001\u5fc3\u8840\u7ba1\u7cfb\u75be\u60a3\u306e\u4e88\u9632\u52b9\u679c\u306e\u53ef\u80fd\u6027\u3068\u3001\u85ac\u3092\u98f2\u3080\u4e0d\u4fbf\u3055\u3001\u30b3\u30b9\u30c8\u3001\u6709\u5bb3\u4e8b\u8c61\u306b\u3064\u3044\u3066\u8b70\u8ad6\u3057\u305f\u4e0a\u3067\u6295\u4e0e\u3092\u6c7a\u5b9a\u3059\u3079\u304d\u3067\u3042\u308b\u3002<\/p>\n
\u3010\u958b\u50ac\u65e5\u3011
\n2012\u5e746\u670827\u65e5<\/p>\n","protected":false},"excerpt":{"rendered":"
\u3010\u6587\u732e\u540d\u3011 \u8457\u8005\u540d\uff1aDean A. Seehusen et al.\u00a0 \u6587\u732e\u30bf\u30a4\u30c8\u30eb\uff1aStatins for Primary Cardiovascular Prevention: Cochrane for Clinicia … \u7d9a\u304d\u3092\u8aad\u3080 \u5fc3\u8840\u7ba1\u75be\u60a3\u306ePrimary Prevention\u306b\u304a\u3051\u308b\u30b9\u30bf\u30c1\u30f3\u306e\u52b9\u679c<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-409","post","type-post","status-publish","format-standard","hentry","category-5"],"_links":{"self":[{"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/posts\/409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=409"}],"version-history":[{"count":1,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/posts\/409\/revisions"}],"predecessor-version":[{"id":410,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=\/wp\/v2\/posts\/409\/revisions\/410"}],"wp:attachment":[{"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hcfm.jp\/journal\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}